Normal mineralization and nanostructure of sclerotic bone in mice overexpressing Fra-1

P. Roschger, Koichi Matsuo, B. M. Misof, W. Tesch, W. Jochum, E. F. Wagner, P. Fratzl, K. Klaushofer

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Increased bone mass due to elevated number of active osteoblasts has been reported for transgenic mice overexpressing the transcription factor Fra-1. To explore the potential of the anabolic action of Fra-1 in treatment of osteoporosis, we examined the integrity of bone matrix generated in Fra-1 transgenic mice. Femora from Fra-1 transgenic (Fra-1 tg) and wild-type littermates were analyzed for bone mineralization density distribution (BMDD) and nanostructure using quantitative backscattered electron imaging (qBEI) and scanning small angle X-ray scattering (scanning-SAXS), respectively. For comparison, we studied mice lacking c-Fos (Fos-/-), which develop osteopetrosis because of the absence of osteoclasts. Morphometrical analysis of metaphyseal spongiosa revealed an up to 5-fold increase in bone volume for Fra-1 transgenic compared to wild type. BMDD indicated a transient lower mineralization of bone for Fra-1 transgenic at 5 and 8 weeks, which became comparable to that of wild-type mice by 8 months. The homogeneity of mineralization was not altered in the Fra-1 transgenic mice at any ages examined. However, it was strikingly reduced in Fos-/- due to an abundance of hypermineralized cartilage. The bone nanostructure did not show abnormalities in Fra-1 transgenic or Fos-/-. These results provide a rationale for the development of therapeutic applications involving Fra-1-induced bone formation.

Original languageEnglish
Pages (from-to)776-782
Number of pages7
JournalBone
Volume34
Issue number5
DOIs
Publication statusPublished - 2004 May

Fingerprint

Physiologic Calcification
Nanostructures
Transgenic Mice
Bone and Bones
Bone Density
Osteopetrosis
Bone Matrix
Osteoclasts
Osteoblasts
Osteogenesis
Femur
Action Potentials
Osteoporosis
Cartilage
Transcription Factors
X-Rays
Electrons
Therapeutics

Keywords

  • Fra-1
  • Sclerotic bone
  • Transgenic

ASJC Scopus subject areas

  • Physiology
  • Hematology

Cite this

Roschger, P., Matsuo, K., Misof, B. M., Tesch, W., Jochum, W., Wagner, E. F., ... Klaushofer, K. (2004). Normal mineralization and nanostructure of sclerotic bone in mice overexpressing Fra-1. Bone, 34(5), 776-782. https://doi.org/10.1016/j.bone.2004.01.004

Normal mineralization and nanostructure of sclerotic bone in mice overexpressing Fra-1. / Roschger, P.; Matsuo, Koichi; Misof, B. M.; Tesch, W.; Jochum, W.; Wagner, E. F.; Fratzl, P.; Klaushofer, K.

In: Bone, Vol. 34, No. 5, 05.2004, p. 776-782.

Research output: Contribution to journalArticle

Roschger, P, Matsuo, K, Misof, BM, Tesch, W, Jochum, W, Wagner, EF, Fratzl, P & Klaushofer, K 2004, 'Normal mineralization and nanostructure of sclerotic bone in mice overexpressing Fra-1', Bone, vol. 34, no. 5, pp. 776-782. https://doi.org/10.1016/j.bone.2004.01.004
Roschger, P. ; Matsuo, Koichi ; Misof, B. M. ; Tesch, W. ; Jochum, W. ; Wagner, E. F. ; Fratzl, P. ; Klaushofer, K. / Normal mineralization and nanostructure of sclerotic bone in mice overexpressing Fra-1. In: Bone. 2004 ; Vol. 34, No. 5. pp. 776-782.
@article{6dc125c2b25a4f748a54c6e26284d38a,
title = "Normal mineralization and nanostructure of sclerotic bone in mice overexpressing Fra-1",
abstract = "Increased bone mass due to elevated number of active osteoblasts has been reported for transgenic mice overexpressing the transcription factor Fra-1. To explore the potential of the anabolic action of Fra-1 in treatment of osteoporosis, we examined the integrity of bone matrix generated in Fra-1 transgenic mice. Femora from Fra-1 transgenic (Fra-1 tg) and wild-type littermates were analyzed for bone mineralization density distribution (BMDD) and nanostructure using quantitative backscattered electron imaging (qBEI) and scanning small angle X-ray scattering (scanning-SAXS), respectively. For comparison, we studied mice lacking c-Fos (Fos-/-), which develop osteopetrosis because of the absence of osteoclasts. Morphometrical analysis of metaphyseal spongiosa revealed an up to 5-fold increase in bone volume for Fra-1 transgenic compared to wild type. BMDD indicated a transient lower mineralization of bone for Fra-1 transgenic at 5 and 8 weeks, which became comparable to that of wild-type mice by 8 months. The homogeneity of mineralization was not altered in the Fra-1 transgenic mice at any ages examined. However, it was strikingly reduced in Fos-/- due to an abundance of hypermineralized cartilage. The bone nanostructure did not show abnormalities in Fra-1 transgenic or Fos-/-. These results provide a rationale for the development of therapeutic applications involving Fra-1-induced bone formation.",
keywords = "Fra-1, Sclerotic bone, Transgenic",
author = "P. Roschger and Koichi Matsuo and Misof, {B. M.} and W. Tesch and W. Jochum and Wagner, {E. F.} and P. Fratzl and K. Klaushofer",
year = "2004",
month = "5",
doi = "10.1016/j.bone.2004.01.004",
language = "English",
volume = "34",
pages = "776--782",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Normal mineralization and nanostructure of sclerotic bone in mice overexpressing Fra-1

AU - Roschger, P.

AU - Matsuo, Koichi

AU - Misof, B. M.

AU - Tesch, W.

AU - Jochum, W.

AU - Wagner, E. F.

AU - Fratzl, P.

AU - Klaushofer, K.

PY - 2004/5

Y1 - 2004/5

N2 - Increased bone mass due to elevated number of active osteoblasts has been reported for transgenic mice overexpressing the transcription factor Fra-1. To explore the potential of the anabolic action of Fra-1 in treatment of osteoporosis, we examined the integrity of bone matrix generated in Fra-1 transgenic mice. Femora from Fra-1 transgenic (Fra-1 tg) and wild-type littermates were analyzed for bone mineralization density distribution (BMDD) and nanostructure using quantitative backscattered electron imaging (qBEI) and scanning small angle X-ray scattering (scanning-SAXS), respectively. For comparison, we studied mice lacking c-Fos (Fos-/-), which develop osteopetrosis because of the absence of osteoclasts. Morphometrical analysis of metaphyseal spongiosa revealed an up to 5-fold increase in bone volume for Fra-1 transgenic compared to wild type. BMDD indicated a transient lower mineralization of bone for Fra-1 transgenic at 5 and 8 weeks, which became comparable to that of wild-type mice by 8 months. The homogeneity of mineralization was not altered in the Fra-1 transgenic mice at any ages examined. However, it was strikingly reduced in Fos-/- due to an abundance of hypermineralized cartilage. The bone nanostructure did not show abnormalities in Fra-1 transgenic or Fos-/-. These results provide a rationale for the development of therapeutic applications involving Fra-1-induced bone formation.

AB - Increased bone mass due to elevated number of active osteoblasts has been reported for transgenic mice overexpressing the transcription factor Fra-1. To explore the potential of the anabolic action of Fra-1 in treatment of osteoporosis, we examined the integrity of bone matrix generated in Fra-1 transgenic mice. Femora from Fra-1 transgenic (Fra-1 tg) and wild-type littermates were analyzed for bone mineralization density distribution (BMDD) and nanostructure using quantitative backscattered electron imaging (qBEI) and scanning small angle X-ray scattering (scanning-SAXS), respectively. For comparison, we studied mice lacking c-Fos (Fos-/-), which develop osteopetrosis because of the absence of osteoclasts. Morphometrical analysis of metaphyseal spongiosa revealed an up to 5-fold increase in bone volume for Fra-1 transgenic compared to wild type. BMDD indicated a transient lower mineralization of bone for Fra-1 transgenic at 5 and 8 weeks, which became comparable to that of wild-type mice by 8 months. The homogeneity of mineralization was not altered in the Fra-1 transgenic mice at any ages examined. However, it was strikingly reduced in Fos-/- due to an abundance of hypermineralized cartilage. The bone nanostructure did not show abnormalities in Fra-1 transgenic or Fos-/-. These results provide a rationale for the development of therapeutic applications involving Fra-1-induced bone formation.

KW - Fra-1

KW - Sclerotic bone

KW - Transgenic

UR - http://www.scopus.com/inward/record.url?scp=2342593346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342593346&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2004.01.004

DO - 10.1016/j.bone.2004.01.004

M3 - Article

VL - 34

SP - 776

EP - 782

JO - Bone

JF - Bone

SN - 8756-3282

IS - 5

ER -